Literature DB >> 16601949

Developing evidence-based guidelines for management of alimentary mucositis: process and pitfalls.

Dorothy M Keefe1, Douglas E Peterson, Mark M Schubert.   

Abstract

INTRODUCTION: It is important yet difficult to maintain currency in clinical oncology practice. The emergence of new diagnostic technologies and new paradigms for cancer treatment combine to produce a rapidly changing clinical approach to patients aided by the increasing use of multidisciplinary care teams and development of evidence-based protocols.
METHODS: Teams of experts review the literature in a given area and produce management guidelines and protocols for use by practicing clinicians. Traditionally within Hematology/Oncology, these guidelines have been directed to management of a given tumor type. However, in recent years, attention has increasingly turned to supportive oncology; for example, there are now management guidelines for conditions such as neutropenic fever [Hughes et al. Clinical Infectious Diseases 34(6):730-751, 2002], antiemetic (The Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer Annals of Oncology 17:20-28, 2006) and most recently, mucositis [Rubenstein et al. Cancer 100(9 Suppl):2026-2046, 2004]. It is critical that any guideline process should include education, evaluation, and timely update in its remit, because guidelines become highly compromised if their existence is not widely known, if they do not facilitate clinical practice, or if they are not reflective of contemporary medical literature.
RESULTS: The Mucositis Study Group (MSG) of the Multinational Association for Supportive Care in Cancer/International Society for Oral Oncology was created in 1998 to specifically address the multiprofessional approach to clinical care, research, and education associated with mucosal injury in cancer patients. A specific outcome has been the development of evidence-based guidelines for the management of mucositis [Rubenstein et al. Cancer 100(9 Suppl):2026-2046, 2004; The Mucositis Study Group of MASCC/ISSO 2005]. The original guidelines [Rubenstein et al. Cancer 100(9 Suppl):2026-2046, 2004] and a companion paper discussing the science behind mucositis [Sonis et al. Cancer 100(9):1995-2025, 2004], were published in 2004. The MSG has recently updated the guidelines [The Mucositis Study Group of MASCC/ISSO 2005]. DISCUSSION: This paper discusses the process involved and the lessons learned that might help other groups planning to undertake a similar project.

Entities:  

Mesh:

Year:  2006        PMID: 16601949     DOI: 10.1007/s00520-006-0059-0

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  16 in total

1.  2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer.

Authors:  Walter T Hughes; Donald Armstrong; Gerald P Bodey; Eric J Bow; Arthur E Brown; Thierry Calandra; Ronald Feld; Philip A Pizzo; Kenneth V I Rolston; Jerry L Shenep; Lowell S Young
Journal:  Clin Infect Dis       Date:  2002-02-13       Impact factor: 9.079

2.  Rating the quality of evidence for clinical practice guidelines.

Authors:  D C Hadorn; D Baker; J S Hodges; N Hicks
Journal:  J Clin Epidemiol       Date:  1996-07       Impact factor: 6.437

3.  Promulgation of guidelines for mucositis management: educating health care professionals and patients.

Authors:  Deborah B McGuire; Judith Johnson; Cesar Migliorati
Journal:  Support Care Cancer       Date:  2006-04-29       Impact factor: 3.603

Review 4.  The role of basic oral care and good clinical practice principles in the management of oral mucositis.

Authors:  Deborah B McGuire; Maria Elvira P Correa; Judith Johnson; Patricia Wienandts
Journal:  Support Care Cancer       Date:  2006-04-25       Impact factor: 3.603

Review 5.  Alimentary tract mucositis in cancer patients: impact of terminology and assessment on research and clinical practice.

Authors:  Douglas E Peterson; Dorothy M Keefe; Ronald D Hutchins; Mark M Schubert
Journal:  Support Care Cancer       Date:  2006-04-26       Impact factor: 3.603

Review 6.  Anti-inflammatory agents in the management of alimentary mucositis.

Authors:  Rajesh V Lalla; Mark M Schubert; Rene-Jean Bensadoun; Dorothy Keefe
Journal:  Support Care Cancer       Date:  2006-03-25       Impact factor: 3.603

Review 7.  Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.

Authors:  Jeffrey A Jones; Elenir B C Avritscher; Catherine D Cooksley; Marisol Michelet; B Nebiyou Bekele; Linda S Elting
Journal:  Support Care Cancer       Date:  2006-04-07       Impact factor: 3.603

8.  Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference.

Authors:  F Roila; P J Hesketh; J Herrstedt
Journal:  Ann Oncol       Date:  2005-11-28       Impact factor: 32.976

9.  Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis.

Authors:  Edward B Rubenstein; Douglas E Peterson; Mark Schubert; Dorothy Keefe; Deborah McGuire; Joel Epstein; Linda S Elting; Philip C Fox; Catherine Cooksley; Stephen T Sonis
Journal:  Cancer       Date:  2004-05-01       Impact factor: 6.860

Review 10.  Gastrointestinal mucositis: a new biological model.

Authors:  Dorothy M K Keefe
Journal:  Support Care Cancer       Date:  2003-11-05       Impact factor: 3.603

View more
  9 in total

Review 1.  Mucositis guidelines: what have they achieved, and where to from here?

Authors:  Dorothy M K Keefe
Journal:  Support Care Cancer       Date:  2006-03-30       Impact factor: 3.603

2.  The MASCC/ISOO Mucositis Guidelines Update: introduction to the first set of articles.

Authors:  Rajesh V Lalla
Journal:  Support Care Cancer       Date:  2012-11-17       Impact factor: 3.603

Review 3.  Systematic review of basic oral care for the management of oral mucositis in cancer patients.

Authors:  Deborah B McGuire; Janet S Fulton; Jumin Park; Carlton G Brown; M Elvira P Correa; June Eilers; Sharon Elad; Faith Gibson; Loree K Oberle-Edwards; Joanne Bowen; Rajesh V Lalla
Journal:  Support Care Cancer       Date:  2013-09-10       Impact factor: 3.603

4.  Healing action of topical chamomile on 5-fluoracil induced oral mucositis in hamster.

Authors:  Vanessa C S Pavesi; Talita C C Lopez; Marco A T Martins; Manoel Sant'Ana Filho; Sandra K Bussadori; Kristianne P S Fernandes; Raquel A Mesquita-Ferrari; Manoela D Martins
Journal:  Support Care Cancer       Date:  2010-04-28       Impact factor: 3.603

5.  Methodology for the MASCC/ISOO Mucositis Clinical Practice Guidelines Update.

Authors:  J M Bowen; S Elad; R D Hutchins; R V Lalla
Journal:  Support Care Cancer       Date:  2012-09-09       Impact factor: 3.603

6.  Oral administration of cystine and theanine attenuates 5-fluorouracil-induced intestinal mucositis and diarrhea by suppressing both glutathione level decrease and ROS production in the small intestine of mucositis mouse model.

Authors:  Junya Yoneda; Sachiko Nishikawa; Shigekazu Kurihara
Journal:  BMC Cancer       Date:  2021-12-18       Impact factor: 4.430

7.  New pathways for alimentary mucositis.

Authors:  Joanne M Bowen; Dorothy M K Keefe
Journal:  J Oncol       Date:  2008-09-23       Impact factor: 4.375

8.  Chimonanthus nitens var. salicifolius Aqueous Extract Protects against 5-Fluorouracil Induced Gastrointestinal Mucositis in a Mouse Model.

Authors:  Zhenze Liu; Jun Xi; Sven Schröder; Weigang Wang; Tianpei Xie; Zhugang Wang; Shisan Bao; Jian Fei
Journal:  Evid Based Complement Alternat Med       Date:  2013-12-03       Impact factor: 2.629

9.  Dipeptidyl-peptidase-4 (DPP-4) inhibitor ameliorates 5-flurouracil induced intestinal mucositis.

Authors:  Jung Min Lee; In Kyung Yoo; Jae Min Lee; Seung Han Kim; Hyuk Soon Choi; Eun Sun Kim; Bora Keum; Yeon Seok Seo; Yoon Tae Jeen; Hoon Jai Chun; Hong Sik Lee; Soon Ho Um; Chang Duck Kim
Journal:  BMC Cancer       Date:  2019-10-29       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.